Back to Search
Start Over
[Recurrent atypical hemolytic uremic syndrome after renal transplantation: treatment with eculizumab].
- Source :
-
Medicina [Medicina (B Aires)] 2018; Vol. 78 (2), pp. 119-122. - Publication Year :
- 2018
-
Abstract
- Atypical hemolytic uremic syndrome (aHUS) is a rare entity. It is characterized by a thrombotic microangiopathy (nonimmune hemolytic anemia, thrombocytopenia, and acute renal failure), with a typical histopathology of thickening of capillary and arteriolar walls and an obstructive thrombosis of the vascular lumen. The syndrome is produced by a genetic or acquired deregulation of the alternative pathway of the complement system, with high rates of end stage renal disease, post-transplant recurrence, and high mortality. Mutations associated with factor H, factor B and complement C3 show the worst prognosis. Even though plasma therapy is occasionally useful, eculizumab is effective both for treatment and prevention of post-transplant recurrence. We describe here an adult case of congenital aHUS (C3 mutation) under preventive treatment with eculizumab after renal transplantation, with neither disease recurrence nor drug-related adverse events after a 36-months follow-up.
- Subjects :
- Acute Kidney Injury complications
Acute Kidney Injury surgery
Adolescent
Female
Graft Rejection drug therapy
Humans
Antibodies, Monoclonal, Humanized therapeutic use
Atypical Hemolytic Uremic Syndrome drug therapy
Atypical Hemolytic Uremic Syndrome etiology
Immunosuppressive Agents therapeutic use
Kidney Transplantation adverse effects
Subjects
Details
- Language :
- Spanish; Castilian
- ISSN :
- 0025-7680
- Volume :
- 78
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Medicina
- Publication Type :
- Academic Journal
- Accession number :
- 29659362